Listed times are in Central European Time (CET)

WELCOME TO DAY ONE

Chair: Marco Hofmann

OPENING KEYNOTE LECTURE

Piro Lito Memorial Sloan Kettering Cancer Center, USA

'A ‘new’ old approach to inactivate RAS'

Q&A 13:40-13:55

Miriam Molina Arcas Francis Crick Institute, UK

'Rational approaches to combine KRAS inhibitors and immunotherapies in lung cancer'

Q&A 14:15-14:25

Saptaparna Mukherjee Francis Crick Institute, UK

Proffered Paper 1: 'MYC and KRASG12C Cooperation Drives Immune-Evasive Tumour Progression in Lung Adenocarcinoma'

Q&A 14:35-14:40

REFRESHMENT BREAK

Chair: Anna Obenauf

Sandra Misale John Hopkins University, USA

'Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma'

Q&A 15:20-15:30

Robert Kortum Uniformed Services University, USA

Proffered Paper 2: 'SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma'

Q&A 15:40-15:45

Mallika Singh Revolution Medicines, USA

'Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors'

Q&A 16:05-16:15

POSTER SPOTLIGHTS

TRANSITION BREAK

VIRTUAL POSTER SESSION ONE

Scheduled to end at 17:35 CET

Listed times are in Central European Time (CET)

VIRTUAL POSTER SESSION TWO

Scheduled to end at 13:30 CET

WELCOME TO DAY TWO

Chair: Chiara Ambrogio

Marco Hofmann Boehringer Ingelheim, Austria

'Targeting the RAS Signaling Pathway: Inhibitors and Mechanisms of Resistance'

Q&A 14:25-14:35

Alberto Bardelli University of Torino, Italy

'Adaptive cancer mutability in response to targeted therapies'

Q&A 14:55-15:05

Christian Umkehrer Boehringer Ingelheim, Austria

Proffered Paper 3: 'Dissecting the clonal evolution of resistance to KRAS inhibitors through genetic barcoding and scRNAseq'

Q&A 15:15-15:20

REFRESHMENT BREAK

Chair: René Bernards

Marina Pasca di Magliano University of Michigan Medicine School, USA

'Oncogenic KRAS mediated regulation of the pancreatic cancer microenvironment'

Q&A 16:00-16:10

Gonzalo Aizpurua Spanish National Cancer Research Centre, Spain

Proffered Paper 4: 'Identifying RAF1 degraders as a therapeutic approach in KRAS-driven lung tumors'

Q&A 16:20-16:25

CLOSING KEYNOTE LECTURE

Colin Lindsay Manchester Cancer Research Centre, UK

'Bedside to bench to bedside again: leveraging KRAS precision medicine for optimum clinical benefit'

Q&A 16:55-17:10

DISCUSSION SESSION

René Bernards, Anna Obenauf, Marco Hofmann & Chiara Ambrogio

'New challenges for old therapeutic targets: What's next?'

SUMMARY AND CLOSE